43 results about "Supraventricular tachycardia" patented technology

A cardiac monitor is provided that monitors the condition of the heart of a cardiac patient and generates signals indicating one of several conditions, such as supraventricular tachycardia, ventricular tachycardia and ventricular fibrillation. In order to generate these signals, the ECG from the patient is analyzed to determine a cardiac interval and heart rate, as well as a waveform factor and a waveform factor irregularity. The waveform factor is derived from the average of the ECG amplitudes during a cardiac interval and the peak value of the ECG during the same interval. Preferably, a running average is calculated over several intervals. This waveform factor is then used to detect shockable ventricular arrhythmia. The waveform factor irregularity is indicative of the variability of the waveform factor and is used to differentiate between ventricular tachycardia and ventricular defibrillation.

A method and system for discrimination of supraventricular tachycardia and ventricular tachycardia events. Morphological features points are extracted from normal sinus rhythm (NSR) complexes and used to generate a NSR template. A numerical convolution is performed using the NSR template and the feature points for each sensed NSR to give a NSR filter output. Using a plurality of NSR complexes, a median NSR filter output template is determined, where the median NSR filter output template has a median value for each value in the NSR filter output. The median NSR filter output template is then used during a tachycardia event to distinguish tachycardia events as either ventricular tachycardia events or supraventricular tachycardia events.

An implantable cardioverter/defibrillator includes a tachycardia detection system that detects one-to-one (1:1) tachycardia, which is a tachycardia with a one-to-one relationship between atrial and ventricular contractions. When the 1:1 tachycardia is detected, the system discriminates ventricular tachycardia (VT) from supraventricular tachycardia (SVT) based on analysis of a cardiac time interval. Examples of the cardiac time interval include an atrioventricular interval (AVI) and a ventriculoatrial interval (VAI). A template time interval is created during a known normal sinus rhythm. The system measures a tachycardia time interval after detecting the 1:1 tachycardia, and indicates a VT detection if the tachycardia time interval differs from the template time interval by at least a predetermined percentage of the template time interval.

The present invention is a cardiac rhythm-monitoring device, which allows patients to perform a preliminary screening for supraventricular arrhythmia. The device detects beat-to-beat heart rhythms (i.e. the R-R interval between individual heart beats) and performs a screening test to determine if there are indications of arrhythmia. The test looks for variance in the R-R interval that is outside of the normal range, either using a pre-constructed chart based upon general population studies to determine the normal range of variance or using normal distribution analysis of the patient's own heart rhythm to determine the normal range of variance for determining irregular heartbeats, and if there are multiple irregularities within the sensed time frame, the patient is warned of potential supraventricular arrhythmia. By sensing both electrical impulses form the heart and mechanical responses to the heartbeat, the device may augment its analysis.

A method and system for determining the mechanism of cardiac arrhythmia in a patient is disclosed. The method basically entails measuring the impedance of cardiac tissue in a portion of the patient's heart using a catheter during an episode of supraventricular tachycardia to produce an iso-impedance map of that cardiac tissue on a video display and analyzing the pattern of the iso-impedance map to differentiate focal arrhythmia caused by a circumscribed region of focal firing and reentrant arrhythmia caused by a macroreentrant circuit. The method can also be used to identify regions of coherent rapidly conducting tissue e.g., Bachman's bundle or the inferoposterior pathway insertion points, to identify focal “mother rotors” throughout the left atrium that may participate in the generation and maintenance of atrial fibrillation and to identify areas of CAFE (complex atrial/fractionated electrograms) that truly reflect these mother rotors.

An implantable medical device (IMD) and methods of operating the same to treat a tachyarrhythmia are disclosed herein. In accordance with this method, an arrhythmia of the heart is classified based on one or more supraventricular tachycardia (SVT) rejection rules, which differentiate between a first group of heart rhythms that do not require treatment and a second group of heart rhythms that possibly require treatment. Diagnostic/therapeutic pacing can then be performed to further discriminate the second group of heart rhythms as being within a first sub-group of heart rhythms and a second sub-group of heart rhythms which are to be treated by applying a ventricular tachycardia (VT)/ventricular fibrillation (VF) therapy sequence. In another implementation, the order in which the IMD performs diagnostic/therapeutic pacing and analyzes passive detection and classification criteria can be reversed.

The invention relates to implementable medical equipment with a ventricular tachycardia diagnosis function. According to the implementable medical equipment with the ventricular tachycardia diagnosisfunction, ventricular tachycardia counting and template matching algorithms are combined, and heart rate suddenness judgement and multistage ventricular tachycardia counting thresholds are set; ventricular tachycardia counting is conducted if a sudden heart rate is acquired, and when a ventricular tachycardia count value reaches a sampling threshold, QRS waveform sampling is conducted; when the ventricular tachycardia count value reaches a matching threshold, sampled real-time heart rate QRS waveforms match sinus heart rate QRS waveform templates; and when the ventricular tachycardia count value reaches a diagnosis threshold, if the number of sampled QRS waveforms which cannot match QRS waveform templates reaches a ventricular tachycardia threshold, ventricular tachycardia is diagnosed. Bymeans of the scheme, supraventricular tachycardia and ventricular tachycardia can be distinguished, so that therapeutic errors are prevented.

An implantable cardiac stimulator includes a cardioversion/defibrillation unit connected to at least one electrode pair for generation and delivery of cardioversion or defibrillation shocks; an atrial sensing unit detecting atrial contraction, and outputting an atrial sensing signal indicating a atrial event when an atrial contraction is detected; a ventricular sensing unit detecting ventricular contraction, and outputting a ventricular sensing signal when a ventricular contraction is detected; a tachycardia detection unit connected to the atrial and ventricular sensing units and detecting a tachycardia, and classifying it as a ventricular tachycardia (VT) or as a supraventricular tachycardia (SVT); and a treatment control unit designed to trigger at least one atrial cardioversion shock when a ventricular rhythm detected by the ventricular sensing unit is faster than a programmed frequency limit, and the tachycardia detection unit classifies an SVT as an atrial fibrillation (AFib).

The invention provides a system for treating arrhythmia by adopting a pulsed electric field ablation technology. The system comprises a voltage pulse system console, a pace-making and ECG unit and anablation catheter. The voltage pulse system console comprises an electrical pulse generator, a controller, a human machine interface and a converter. The pace-making and ECG unit comprises an ECG recorder, a pace-making catheter, a cardiac stimulator and a mapping catheter, and pace-making electric signals are synchronously transmitted to the voltage pulse system console. The ablation catheter isconnected to the system console through the converter, delivers a voltage pulse waveform within the refractory period of the cardiac cycle based on a pacing signal, and delivers pulsed electric fieldenergy to the ablated tissue through electrodes on the ablation catheter. The ablation catheter comprises a spline basket, an annular catheter entering the pulmonary vein is further arranged at the far end of the spline basket, and large-area irreversible injuries which are locally, linearly, annularly or evenly distributed can be formed, so that the purpose of treating arrhythmia diseases such asatrial repair, supraventricular tachycardia and atrial fibrillation is achieved.

Techniques are described for discriminating ventricular tachycardia (VT) from supraventricular tachycardia (SVT) in circumstances when the ventricular rate exceeds the atrial rate (i.e. V>A). In one example, an initial atrial rate is detected while employing adjustable atrial channel detection parameters that can affect the detection of the true atrial rate—such as a post-ventricular atrial blanking (PVAB) interval or an atrial channel sensitivity level. If the ventricular rate exceeds a VT rate zone threshold with V>A, the device does not immediately deliver high voltage shock therapy as done in other devices. Rather, the device instead selectively adjusts the atrial channel detection parameter(s) to determine if the true atrial rate is equal to the ventricular rate. If so, then such is an indication that the arrhythmia might be SVT rather than VT and various discrimination procedures are employed to distinguish SVT from VT before therapy is delivered.

Implantable cardiac stimulator, with chamber stimulation unit connectable to left/right ventricular stimulation electrode to generate/deliver chamber stimulation pulses for stimulation of ventricle; ventricular sensing unit (VSU) to detect respective chamber contraction and deliver ventricular sensing signal when chamber contraction detected; optional atrial stimulation unit, connectable to atrial stimulation electrode to generate atrial stimulation pulses to stimulate atrium; atrial sensing unit, to detect atrial contraction, deliver atrial sensing signal indicating respective atrial event; tachycardia detection unit, connected to VSU to detect and categorize ventricular/supraventricular tachycardia; treatment control unit (TCU), triggers chamber stimulation unit to deliver antitachycardiac stimulation (ATP); analyzer unit, connected to atrial sensing unit and TCU. Analyzes atrial events from sensing unit before/during/after delivering antitachycardiac stimulation for atrial rhythm pattern during ventricular ATP by comparison atrial rhythm pattern immediately before ATP and to trigger TCU as function of ATP response signal representing comparison result for selection of the following antitachycardiac treatment.

The invention relates to the technical field of medical apparatuses, and in particular to a vascular radio-frequency ablation electrode catheter provided with claw-shaped catheter branches; a radio-frequency ablation working section is arranged on the front section of the vascular radio-frequency ablation electrode catheter , a catheter body section is arranged on the middle section of the vascular radio-frequency ablation electrode catheter and a control handle section is arranged on the rear section of the vascular radio-frequency ablation electrode catheter; the eight radio-frequency catheter branches extend from a peripheral direction of the radio-frequency ablation working section; the eight radio-frequency catheter branches are integrally represented as claw-shaped structures; and at least one ablation electrode is connected to the head end of each radio-frequency catheter branch. The vascular radio-frequency ablation electrode catheter provided by the invention has the beneficial effects that in practical clinical treatment, the vascular radio-frequency ablation electrode catheter provided with the claw-shaped catheter branches provided by the invention can be applied to various blood vessels differing in diameter and can be used for conducting radio-frequency ablation therapy on cardiac muscle tissues in a complex part, such as for vascular ablation of such diseases as paroxysmal atrial tachycardia, supraventricular tachycardia, atrial flutter, atrial fibrillation, resistant hypertension and the like.

Techniques are described for discriminating ventricular tachycardia (VT) from supraventricular tachycardia (SVT) using an implantable medical device capable of multi-site ventricular sensing. In one example, ventricular depolarization events are detected within a patient by the implantable device during a tachyarrhythmia, at both a left ventricular sensing site and a right ventricular sensing site. Ventricular event timing differences are then ascertained. The device compares the ventricular event timing differences detected during the tachyarrhythmia with predetermined supraventricular event timing differences for the patient, such as event timing differences previously detected within the patient during sinus rhythm or extrapolated from sinus rhythm values. The device then distinguishes VT from SVT based on the comparison of the event timing differences detected during the tachyarrhythmia with the predetermined supraventricular event timing differences. Morphological waveform analysis can also be performed, when needed, to further distinguish VT from SVT.